In malaria-endemic countries, 350 million people are predicted to be deficient in an enzyme that means they can suffer severe complications from taking primaquine, a key drug for treating relapsing malaria, according to a study funded by the Wellcome Trust and published in this week's PLOS Medicine.
This finding is important as primaquine is recommended in the global action plan to eliminate malaria and is the only drug to prevent malaria relapse. The benefits of implementing a treatment program with this drug need to be weighed against the potential harm to a substantial proportion of the population (up to 8%) who may have G6PD deficiency: a genetic defect reducing glucose-6-phosphate dehydrogenase enzyme activitiy. Individuals with G6PD deficiency who are given primaquine can experience a severe complication – the breakdown of their red blood cells (hemolysis).
The authors from Indonesia, Kenya, the Philippines, and the United Kingdom, led by Rosalind Howes from the University of Oxford, reached these conclusions by inputting information about the frequency of G6PD deficiency from community surveys into a geostatistical model. Using the model, the authors predicted that G6PD deficiency is widespread across malaria-endemic regions, with the lowest frequencies in North and South America and the highest frequency in tropical Africa and the Arabian Peninsula.
Dr Howe explains: "Malaria control and elimination are a top priority on the global health agenda. Yet, a key drug to help achieve this goal remains too dangerous for widespread use. We have developed a map of this risk factor, G6PD deficiency, and find it to be very common across many malaria endemic regions. Much work remains to be done to fully understand this disease, notably its genetic diversity."
The authors found that the predicted frequency of G6PD deficiency varied considerably over relatively short distances in many areas but the overall frequency was 8% in malaria-endemic countries, corresponding to about 350 million affected individuals. In countries that are currently planning to implement malaria elimination programs, the frequency was 5.3%, corresponding to 100 million affected individuals.
When the authors took the severity of the G6PD deficiency (the more severe the deficiency, the higher the risk of hemolysis), they found that the greatest risk was across Asia, where severe G6PD variants are commonly inherited.
The authors say: The prominence of G6PD deficiency represents a barrier to current options for malaria elimination therapy."
They continue: "The complexity and diversity of both malaria epidemiology and G6PD deficiency mean that no single solution will be applicable for ensuring safe and effective primaquine treatment."
Public Library of Science: http://www.plos.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
The World Health Organization says an outbreak of the deadly Ebola virus in West Africa has been linked to the deaths of more than 120 people. As of Monday, the organization recorded a total of 200 suspected or confirmed cases of Ebola, which is normally found in central or eastern Africa, in…
To see if low blood sugar sours even good relationships, scientists used an unusual tool: voodoo dolls representing spouses. As hunger levels rose, so did the number of pins.
A Beijing artist who collected a jar of air from Provence, France, sold it at auction "to question China's foul air and express dissatisfaction."
With purported activity against cardiac disease, cancer and even ageing, the pressure on resveratrol to deliver is enormous
Health workers responding to an Ebola outbreak in Guinea had no maps to go on, so they turned to the internet for help
Researchers ignited a debate three years ago when they changed a deadly flu virus so that it could spread between people. Only five mutations are needed to turn the virus into a pandemic threat.
Hundreds of millions of pounds have been wasted on Tamiflu, a drug for flu that may work no better than paracetamol, a landmark analysis says.
Giving heroin users vouchers in exchange for taking vaccines is the stuff of tabloid headlines. But it works, says addiction researcher Nicola Metrebian
An initiative to share the control group data from 34 clinical trials of cancer drugs could lead to more efficient trials and better outcomes for patients
If you know Ciroc and Patron, you may well be listening to a lot of songs that name-check brand-name alcohol. And if you're a teenager, you may be binge drinking a lot more, researchers say.